Evidence of positive selection at codon sites localized in extracellular domains of mammalian CC motif chemokine receptor proteins.
BACKGROUND
CC chemokine receptor proteins (CCR1 through CCR10) are seven-transmembrane G-protein coupled receptors whose signaling pathways are known for their important roles coordinating immune system responses through targeted trafficking of white blood cells. In addition, some of these receptors have been identified as fusion proteins for viral pathogens: for example, HIV-1 strains utilize CCR5, CCR2 and CCR3 proteins to obtain cellular entry in humans. The extracellular domains of these receptor proteins are involved in ligand-binding specificity as well as pathogen recognition interactions.In mammals, the majority of chemokine receptor genes are clustered together; in humans, seven of the ten genes are clustered in the 3p21-24 chromosome region. Gene conversion events, or exchange of DNA sequence between genes, have been reported in chemokine receptor paralogs in various mammalian lineages, especially between the cytogenetically closely located pairs CCR2/5 and CCR1/3. Datasets of mammalian orthologs for each gene were analyzed separately to minimize the potential confounding impact of analyzing highly similar sequences resulting from gene conversion events.Molecular evolution approaches and the software package Phylogenetic Analyses by Maximum Likelihood (PAML) were utilized to investigate the signature of selection that has acted on the mammalian CC chemokine receptor (CCR) gene family. The results of neutral vs. adaptive evolution (positive selection) hypothesis testing using Site Models are reported. In general, positive selection is defined by a ratio of nonsynonymous/synonymous nucleotide changes (dN/dS, or omega) >1.


RESULTS
Of the ten mammalian CC motif chemokine receptor sequence datasets analyzed, only CCR2 and CCR3 contain amino acid codon sites that exhibit evidence of positive selection using site based hypothesis testing in PAML. Nineteen of the twenty codon sites putatively indentified as likely to be under positive selection code for amino acid residues located in extracellular domains of the receptor protein products.


CONCLUSIONS
These results suggest that amino acid residues present in intracellular and membrane-bound domains are more selectively constrained for functional signal transduction and homo- or heterodimerization, whereas amino acid residues in extracellular domains of these receptor proteins evolve more quickly, perhaps due to heightened selective pressure resulting from ligand-binding and pathogen interactions of extracellular domains.
Metzger
Kelsey J
KJ
Department of Biological Sciences, Idaho State University, Pocatello, 83209, USA. kmetzger@umn.edu
Thomas
Michael A
MA
D000818:Animals; D003062:Codon; D006801:Humans; D054388:Receptors, CCR / Q000737:chemistry / Q000235:genetics* / Q000276:immunology; D012641:Selection, Genetic
D003062:Codon; D054388:Receptors, CCR
Crit Rev Oral Biol Med. 1995;6(2):109-18
7548618
J Struct Funct Genomics. 2003;3(1-4):201-12
12836699
J Clin Invest. 1997 Aug 1;100(3):497-502
9239395
Trends Genet. 2000 Jun;16(6):276-7
10827456
Genomics. 2007 Aug;90(2):213-24
17544254
ACS Chem Biol. 2007 Nov 20;2(11):735-44
18030990
Gene. 2000 Apr 4;246(1-2):239-45
10767545
Mol Biol Evol. 2005 Apr;22(4):1107-18
15689528
Mol Pharmacol. 2002 Sep;62(3):729-36
12181451
Int J Immunogenet. 2007 Oct;34(5):321-4
17845301
J Mol Model. 2003 Oct;9(5):329-36
14517611
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Nov;150(2):191-204
17426779
Annu Rev Immunol. 1997;15:675-705
9143704
Nucleic Acids Res. 2003 Jul 1;31(13):3856-8
12824436
Science. 1996 Jun 28;272(5270):1955-8
8658171
Syst Biol. 2007 Aug;56(4):673-84
17661234
J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):509-17
15793360
Mol Biol Evol. 2001 Aug;18(8):1585-92
11470850
Curr Biol. 2007 Apr 3;17(7):R230-1
17407748
J Virol. 2003 Nov;77(22):12310-8
14581567
Mol Immunol. 2006 Mar;43(8):1221-31
16102831
Curr Med Chem. 2008;15(13):1297-304
18537609
Mol Biol Evol. 2007 Aug;24(8):1586-91
17483113
Immunogenetics. 2006 Jun;58(5-6):494-501
16596402
J Biol Chem. 1999 Jun 4;274(23):16228-34
10347178
J Clin Immunol. 2006 Sep;26(5):476-84
16865553
Biosci Rep. 2006 Oct;26(5):325-39
17024562
J Hered. 2008 Sep-Oct;99(5):500-11
18502735
Bioinformatics. 1998;14(9):817-8
9918953
Bioinformatics. 2006 Dec 1;22(23):2971-2
17021158
Comput Appl Biosci. 1997 Oct;13(5):555-6
9367129
J Biol Chem. 1998 Aug 7;273(32):19972-6
9685332
J Biol Chem. 2003 Feb 14;278(7):5179-87
12466283
J Infect Dis. 2008 Jan 15;197(2):262-5
18179388
Syst Biol. 1998 Mar;47(1):125-33
12064232
Cytokine. 2006 Feb 7;33(3):171-8
16524739
J Exp Med. 2006 Jan 23;203(1):35-40
16418398
Virology. 2004 Nov 10;329(1):109-18
15476879
Infect Agents Dis. 1994 Apr-Jun;3(2-3):137-54
7812652
APMIS. 2004 Jul-Aug;112(7-8):481-95
15563311
Int J Immunogenet. 2007 Jun;34(3):153-6
17504503
Science. 1994 Mar 25;263(5154):1762-7
8134838
Trends Immunol. 2006 Jul;27(7):308-12
16753343
Hum Mol Genet. 1999;8(10):1939-45
10469847
J Mol Evol. 2009 Jun;68(6):679-87
19471989
Front Biosci (Landmark Ed). 2009 Jan 01;14:540-51
19273084
J Biol Chem. 1999 Nov 5;274(45):32055-62
10542238
J Biol Chem. 2000 Jun 23;275(25):18946-61
10747879
J Leukoc Biol. 1997 Jul;62(1):20-9
9225988
Eur J Immunol. 2005 Apr;35(4):1301-10
15739168
Cardiovasc Res. 2008 May 1;78(2):250-6
18252760
J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):446-54
15021309
J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):309-13
15076247
Annu Rev Immunol. 2000;18:217-42
10837058
Annu Rev Pharmacol Toxicol. 2002;42:469-99
11807180
Biochem Biophys Res Commun. 2008 Dec 5;377(1):93-7
18823943
Science. 1993 Aug 27;261(5125):1182-4
7689250